A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (Iressa) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy.

Trial Profile

A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (Iressa) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 May 2011

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Aug 2007 Status change from recruiting to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top